Globus Medical INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
David D Davidar, a Director of Globus Medical Inc, reported a transaction in 2,500 shares of common stock on July 27, 2026.
NYSE
Director David D. Davidar exercised 25,000 stock options and subsequently sold the shares in a planned transaction.
NYSE
Director Ann Rhoads acquired 25,000 shares of Globus Medical Class A Common Stock through the exercise of stock options.
NYSE
Globus Medical EVP Kelly Huller exercised stock options and immediately sold the acquired shares under a pre-arranged trading plan.
NYSE
Globus Medical Director Leslie V. Norwalk was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical's President and CEO, Keith W. Pfeil, was granted 100,000 stock options with an exercise price of $94.15, vesting over four years.
NYSE
Globus Medical's CFO, Kyle Kline, received a grant of 30,000 stock options with an exercise price of $94.15, vesting over a four-year period.
NYSE
Globus Medical's Executive Chairman, David C. Paul, was granted 100,000 stock options with an exercise price of $94.15, vesting over four years.
NYSE
Globus Medical Director Douglas Andrew was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Director Dan Lemaitre received a grant of 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Director Ann D. Rhoads received 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Inc. Director James R. Tobin was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Inc. Director Stephen T. Zarrilli was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Inc. Director John A. DeFord was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical Director Dan Wolterman was granted 15,000 stock options with an exercise price of $94.15, aligning his interests with long-term shareholder value.
NYSE
Globus Medical Inc. Director David D. Davidar was granted 15,000 stock options with an exercise price of $94.15, vesting on January 1, 2027.
NYSE
Globus Medical's EVP, General Counsel, and Corporate Secretary, Kelly Huller, was granted 40,000 stock options with an exercise price of $94.15, vesting over four years.
NYSE
Globus Medical CFO Kyle Kline filed an amended Form 4 to correct the number of stock options exercised from 5,000 to 4,896 shares of Class A Common Stock.
NYSE
Globus Medical's CFO, Kyle Kline, exercised stock options and subsequently sold the acquired shares for personal financial planning under a Rule 10b5-1 plan.
NYSE
A director at Globus Medical Inc. sold 2,000 shares of Class A Common Stock for $101.1 per share as part of a pre-arranged 10b5-1 trading plan.
NYSE
Globus Medical Director David D. Davidar reported gifting 6,100 shares of Class A Common Stock to a family trust.
NYSE
A director at Globus Medical Inc. sold 4,000 shares of Class A Common Stock for $88.85 per share, reducing their direct beneficial ownership to 12,419 shares.
NYSE
Globus Medical's Executive Chairman, Paul David C, exercised stock options to acquire 34,375 shares of Class A Common Stock.
NYSE
Globus Medical's CFO, Kyle Kline, exercised stock options and sold 18,542 Class A Common Stock shares for $1.67 million under a Rule 10b5-1 plan.
NYSE
Globus Medical's SVP, GC, and Corporate Secretary, Kelly Huller, exercised stock options and subsequently sold 7,500 shares of Class A Common Stock for $90.00 per share.
NYSE
A director at Globus Medical Inc. exercised stock options and subsequently sold 25,000 Class A Common Stock shares.
NYSE
Globus Medical Director Stephen T. Zarrilli executed a pre-planned transaction, exercising stock options and immediately selling 25,000 Class A Common Stock shares.
NYSE
Globus Medical Director Ann D. Rhoads sold 10,000 shares of Class A Common Stock in pre-planned transactions.
NYSE
Globus Medical Director Ann D. Rhoads sold 10,000 shares of Class A Common Stock for a weighted average price of $58.46 per share under a pre-arranged trading plan.
NYSE
Globus Medical's President and CEO, Keith W. Pfeil, was granted 40,000 stock options with an exercise price of $56.34, vesting over four years.